ND630 controls ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003
ND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism. However, the function of ND630 in prostate cancer remains unknown. KIF18B, as an oncogene, plays a vital role in prostate cancer progression. circKIF18B_003 was deri...
Saved in:
Published in | Journal of translational medicine Vol. 21; no. 1; pp. 877 - 22 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
04.12.2023
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | ND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism. However, the function of ND630 in prostate cancer remains unknown. KIF18B, as an oncogene, plays a vital role in prostate cancer progression. circKIF18B_003 was derived from oncogene KIF18B and was markedly overexpressed in prostate cancer tissues. We speculated that oncoprotein KIF18B-derived circRNA circKIF18B_003 might have roles in prostate cancer promotion. The aim of this study was to validate whether ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003.
RT-qPCR was used to analyze the expression of circKIF18B_003 in prostate cancer cell lines and prostate cancer samples. circKIF18B_003 expression was modulated in prostate cancer cells using circKIF18B_003 interference or overexpression plasmid. We examined the function and effects of circKIF18B_003 in prostate cancer cells using CCK-8, colony formation, wound healing, and Transwell invasion assays and xenograft models. Fluorescence in situ hybridization (FISH) was performed to evaluate the localization of circKIF18B_003. RNA immunoprecipitation (RIP), RNA pull down, and luciferase reporter assay were performed to explore the potential mechanism of circKIF18B_003.
The function of ND630 was determined in this study. circKIF18B_003 was overexpressed in prostate cancer tissues, and overexpression of circKIF18B_003 was associated with poor survival outcome of prostate cancer patients. The proliferation, migration, and invasion of prostate cancer cells were enhanced after up-regulation of circKIF18B_003. circKIF18B_003 is mainly located in the cytoplasm of prostate cancer cells, and the RIP and RNA pull down assays confirmed that circKIF18B_003 could act as a sponge for miR-370-3p. Further study demonstrated that up-regulation of circKIF18B_003 increased the expression of ACACA by sponging miR-370-3p. The malignant ability of prostate cancer cells enhanced by overexpression of circKIF18B_003 was reversed by the down-regulation of ACACA. We found that overexpression of circKIF18B_003 was associated with lipid metabolism, and a combination of ND-630 and docetaxel markedly attenuated tumor growth.
ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. ND630 and circKIF18B_003 may represent a novel target for prostate cancer. |
---|---|
AbstractList | Background ND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism. However, the function of ND630 in prostate cancer remains unknown. KIF18B, as an oncogene, plays a vital role in prostate cancer progression. circKIF18B_003 was derived from oncogene KIF18B and was markedly overexpressed in prostate cancer tissues. We speculated that oncoprotein KIF18B-derived circRNA circKIF18B_003 might have roles in prostate cancer promotion. The aim of this study was to validate whether ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. Methods RT-qPCR was used to analyze the expression of circKIF18B_003 in prostate cancer cell lines and prostate cancer samples. circKIF18B_003 expression was modulated in prostate cancer cells using circKIF18B_003 interference or overexpression plasmid. We examined the function and effects of circKIF18B_003 in prostate cancer cells using CCK-8, colony formation, wound healing, and Transwell invasion assays and xenograft models. Fluorescence in situ hybridization (FISH) was performed to evaluate the localization of circKIF18B_003. RNA immunoprecipitation (RIP), RNA pull down, and luciferase reporter assay were performed to explore the potential mechanism of circKIF18B_003. Results The function of ND630 was determined in this study. circKIF18B_003 was overexpressed in prostate cancer tissues, and overexpression of circKIF18B_003 was associated with poor survival outcome of prostate cancer patients. The proliferation, migration, and invasion of prostate cancer cells were enhanced after up-regulation of circKIF18B_003. circKIF18B_003 is mainly located in the cytoplasm of prostate cancer cells, and the RIP and RNA pull down assays confirmed that circKIF18B_003 could act as a sponge for miR-370-3p. Further study demonstrated that up-regulation of circKIF18B_003 increased the expression of ACACA by sponging miR-370-3p. The malignant ability of prostate cancer cells enhanced by overexpression of circKIF18B_003 was reversed by the down-regulation of ACACA. We found that overexpression of circKIF18B_003 was associated with lipid metabolism, and a combination of ND-630 and docetaxel markedly attenuated tumor growth. Conclusion ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. ND630 and circKIF18B_003 may represent a novel target for prostate cancer. Keywords: CircRNAs, Prostate cancer, ACACA, ND630 ND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism. However, the function of ND630 in prostate cancer remains unknown. KIF18B, as an oncogene, plays a vital role in prostate cancer progression. circKIF18B_003 was derived from oncogene KIF18B and was markedly overexpressed in prostate cancer tissues. We speculated that oncoprotein KIF18B-derived circRNA circKIF18B_003 might have roles in prostate cancer promotion. The aim of this study was to validate whether ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. RT-qPCR was used to analyze the expression of circKIF18B_003 in prostate cancer cell lines and prostate cancer samples. circKIF18B_003 expression was modulated in prostate cancer cells using circKIF18B_003 interference or overexpression plasmid. We examined the function and effects of circKIF18B_003 in prostate cancer cells using CCK-8, colony formation, wound healing, and Transwell invasion assays and xenograft models. Fluorescence in situ hybridization (FISH) was performed to evaluate the localization of circKIF18B_003. RNA immunoprecipitation (RIP), RNA pull down, and luciferase reporter assay were performed to explore the potential mechanism of circKIF18B_003. The function of ND630 was determined in this study. circKIF18B_003 was overexpressed in prostate cancer tissues, and overexpression of circKIF18B_003 was associated with poor survival outcome of prostate cancer patients. The proliferation, migration, and invasion of prostate cancer cells were enhanced after up-regulation of circKIF18B_003. circKIF18B_003 is mainly located in the cytoplasm of prostate cancer cells, and the RIP and RNA pull down assays confirmed that circKIF18B_003 could act as a sponge for miR-370-3p. Further study demonstrated that up-regulation of circKIF18B_003 increased the expression of ACACA by sponging miR-370-3p. The malignant ability of prostate cancer cells enhanced by overexpression of circKIF18B_003 was reversed by the down-regulation of ACACA. We found that overexpression of circKIF18B_003 was associated with lipid metabolism, and a combination of ND-630 and docetaxel markedly attenuated tumor growth. ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. ND630 and circKIF18B_003 may represent a novel target for prostate cancer. BackgroundND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism. However, the function of ND630 in prostate cancer remains unknown. KIF18B, as an oncogene, plays a vital role in prostate cancer progression. circKIF18B_003 was derived from oncogene KIF18B and was markedly overexpressed in prostate cancer tissues. We speculated that oncoprotein KIF18B-derived circRNA circKIF18B_003 might have roles in prostate cancer promotion. The aim of this study was to validate whether ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003.MethodsRT-qPCR was used to analyze the expression of circKIF18B_003 in prostate cancer cell lines and prostate cancer samples. circKIF18B_003 expression was modulated in prostate cancer cells using circKIF18B_003 interference or overexpression plasmid. We examined the function and effects of circKIF18B_003 in prostate cancer cells using CCK-8, colony formation, wound healing, and Transwell invasion assays and xenograft models. Fluorescence in situ hybridization (FISH) was performed to evaluate the localization of circKIF18B_003. RNA immunoprecipitation (RIP), RNA pull down, and luciferase reporter assay were performed to explore the potential mechanism of circKIF18B_003.ResultsThe function of ND630 was determined in this study. circKIF18B_003 was overexpressed in prostate cancer tissues, and overexpression of circKIF18B_003 was associated with poor survival outcome of prostate cancer patients. The proliferation, migration, and invasion of prostate cancer cells were enhanced after up-regulation of circKIF18B_003. circKIF18B_003 is mainly located in the cytoplasm of prostate cancer cells, and the RIP and RNA pull down assays confirmed that circKIF18B_003 could act as a sponge for miR-370-3p. Further study demonstrated that up-regulation of circKIF18B_003 increased the expression of ACACA by sponging miR-370-3p. The malignant ability of prostate cancer cells enhanced by overexpression of circKIF18B_003 was reversed by the down-regulation of ACACA. We found that overexpression of circKIF18B_003 was associated with lipid metabolism, and a combination of ND-630 and docetaxel markedly attenuated tumor growth.ConclusionND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. ND630 and circKIF18B_003 may represent a novel target for prostate cancer. ND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism. However, the function of ND630 in prostate cancer remains unknown. KIF18B, as an oncogene, plays a vital role in prostate cancer progression. circKIF18B_003 was derived from oncogene KIF18B and was markedly overexpressed in prostate cancer tissues. We speculated that oncoprotein KIF18B-derived circRNA circKIF18B_003 might have roles in prostate cancer promotion. The aim of this study was to validate whether ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003.BACKGROUNDND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism. However, the function of ND630 in prostate cancer remains unknown. KIF18B, as an oncogene, plays a vital role in prostate cancer progression. circKIF18B_003 was derived from oncogene KIF18B and was markedly overexpressed in prostate cancer tissues. We speculated that oncoprotein KIF18B-derived circRNA circKIF18B_003 might have roles in prostate cancer promotion. The aim of this study was to validate whether ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003.RT-qPCR was used to analyze the expression of circKIF18B_003 in prostate cancer cell lines and prostate cancer samples. circKIF18B_003 expression was modulated in prostate cancer cells using circKIF18B_003 interference or overexpression plasmid. We examined the function and effects of circKIF18B_003 in prostate cancer cells using CCK-8, colony formation, wound healing, and Transwell invasion assays and xenograft models. Fluorescence in situ hybridization (FISH) was performed to evaluate the localization of circKIF18B_003. RNA immunoprecipitation (RIP), RNA pull down, and luciferase reporter assay were performed to explore the potential mechanism of circKIF18B_003.METHODSRT-qPCR was used to analyze the expression of circKIF18B_003 in prostate cancer cell lines and prostate cancer samples. circKIF18B_003 expression was modulated in prostate cancer cells using circKIF18B_003 interference or overexpression plasmid. We examined the function and effects of circKIF18B_003 in prostate cancer cells using CCK-8, colony formation, wound healing, and Transwell invasion assays and xenograft models. Fluorescence in situ hybridization (FISH) was performed to evaluate the localization of circKIF18B_003. RNA immunoprecipitation (RIP), RNA pull down, and luciferase reporter assay were performed to explore the potential mechanism of circKIF18B_003.The function of ND630 was determined in this study. circKIF18B_003 was overexpressed in prostate cancer tissues, and overexpression of circKIF18B_003 was associated with poor survival outcome of prostate cancer patients. The proliferation, migration, and invasion of prostate cancer cells were enhanced after up-regulation of circKIF18B_003. circKIF18B_003 is mainly located in the cytoplasm of prostate cancer cells, and the RIP and RNA pull down assays confirmed that circKIF18B_003 could act as a sponge for miR-370-3p. Further study demonstrated that up-regulation of circKIF18B_003 increased the expression of ACACA by sponging miR-370-3p. The malignant ability of prostate cancer cells enhanced by overexpression of circKIF18B_003 was reversed by the down-regulation of ACACA. We found that overexpression of circKIF18B_003 was associated with lipid metabolism, and a combination of ND-630 and docetaxel markedly attenuated tumor growth.RESULTSThe function of ND630 was determined in this study. circKIF18B_003 was overexpressed in prostate cancer tissues, and overexpression of circKIF18B_003 was associated with poor survival outcome of prostate cancer patients. The proliferation, migration, and invasion of prostate cancer cells were enhanced after up-regulation of circKIF18B_003. circKIF18B_003 is mainly located in the cytoplasm of prostate cancer cells, and the RIP and RNA pull down assays confirmed that circKIF18B_003 could act as a sponge for miR-370-3p. Further study demonstrated that up-regulation of circKIF18B_003 increased the expression of ACACA by sponging miR-370-3p. The malignant ability of prostate cancer cells enhanced by overexpression of circKIF18B_003 was reversed by the down-regulation of ACACA. We found that overexpression of circKIF18B_003 was associated with lipid metabolism, and a combination of ND-630 and docetaxel markedly attenuated tumor growth.ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. ND630 and circKIF18B_003 may represent a novel target for prostate cancer.CONCLUSIONND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. ND630 and circKIF18B_003 may represent a novel target for prostate cancer. Abstract Background ND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism. However, the function of ND630 in prostate cancer remains unknown. KIF18B, as an oncogene, plays a vital role in prostate cancer progression. circKIF18B_003 was derived from oncogene KIF18B and was markedly overexpressed in prostate cancer tissues. We speculated that oncoprotein KIF18B-derived circRNA circKIF18B_003 might have roles in prostate cancer promotion. The aim of this study was to validate whether ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. Methods RT-qPCR was used to analyze the expression of circKIF18B_003 in prostate cancer cell lines and prostate cancer samples. circKIF18B_003 expression was modulated in prostate cancer cells using circKIF18B_003 interference or overexpression plasmid. We examined the function and effects of circKIF18B_003 in prostate cancer cells using CCK-8, colony formation, wound healing, and Transwell invasion assays and xenograft models. Fluorescence in situ hybridization (FISH) was performed to evaluate the localization of circKIF18B_003. RNA immunoprecipitation (RIP), RNA pull down, and luciferase reporter assay were performed to explore the potential mechanism of circKIF18B_003. Results The function of ND630 was determined in this study. circKIF18B_003 was overexpressed in prostate cancer tissues, and overexpression of circKIF18B_003 was associated with poor survival outcome of prostate cancer patients. The proliferation, migration, and invasion of prostate cancer cells were enhanced after up-regulation of circKIF18B_003. circKIF18B_003 is mainly located in the cytoplasm of prostate cancer cells, and the RIP and RNA pull down assays confirmed that circKIF18B_003 could act as a sponge for miR-370-3p. Further study demonstrated that up-regulation of circKIF18B_003 increased the expression of ACACA by sponging miR-370-3p. The malignant ability of prostate cancer cells enhanced by overexpression of circKIF18B_003 was reversed by the down-regulation of ACACA. We found that overexpression of circKIF18B_003 was associated with lipid metabolism, and a combination of ND-630 and docetaxel markedly attenuated tumor growth. Conclusion ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. ND630 and circKIF18B_003 may represent a novel target for prostate cancer. ND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism. However, the function of ND630 in prostate cancer remains unknown. KIF18B, as an oncogene, plays a vital role in prostate cancer progression. circKIF18B_003 was derived from oncogene KIF18B and was markedly overexpressed in prostate cancer tissues. We speculated that oncoprotein KIF18B-derived circRNA circKIF18B_003 might have roles in prostate cancer promotion. The aim of this study was to validate whether ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. RT-qPCR was used to analyze the expression of circKIF18B_003 in prostate cancer cell lines and prostate cancer samples. circKIF18B_003 expression was modulated in prostate cancer cells using circKIF18B_003 interference or overexpression plasmid. We examined the function and effects of circKIF18B_003 in prostate cancer cells using CCK-8, colony formation, wound healing, and Transwell invasion assays and xenograft models. Fluorescence in situ hybridization (FISH) was performed to evaluate the localization of circKIF18B_003. RNA immunoprecipitation (RIP), RNA pull down, and luciferase reporter assay were performed to explore the potential mechanism of circKIF18B_003. The function of ND630 was determined in this study. circKIF18B_003 was overexpressed in prostate cancer tissues, and overexpression of circKIF18B_003 was associated with poor survival outcome of prostate cancer patients. The proliferation, migration, and invasion of prostate cancer cells were enhanced after up-regulation of circKIF18B_003. circKIF18B_003 is mainly located in the cytoplasm of prostate cancer cells, and the RIP and RNA pull down assays confirmed that circKIF18B_003 could act as a sponge for miR-370-3p. Further study demonstrated that up-regulation of circKIF18B_003 increased the expression of ACACA by sponging miR-370-3p. The malignant ability of prostate cancer cells enhanced by overexpression of circKIF18B_003 was reversed by the down-regulation of ACACA. We found that overexpression of circKIF18B_003 was associated with lipid metabolism, and a combination of ND-630 and docetaxel markedly attenuated tumor growth. ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. ND630 and circKIF18B_003 may represent a novel target for prostate cancer. |
ArticleNumber | 877 |
Audience | Academic |
Author | You, Qi Zheng, Qing-Shui Huang, Qi Xue, Xue-Yi Zheng, Wen-Cai Huang, Xu-Yun Wei, Yong Xu, Ning Lin, Fei Wu, Yu-Peng Ke, Zhi-Bin |
Author_xml | – sequence: 1 givenname: Yu-Peng surname: Wu fullname: Wu, Yu-Peng – sequence: 2 givenname: Wen-Cai surname: Zheng fullname: Zheng, Wen-Cai – sequence: 3 givenname: Qi surname: Huang fullname: Huang, Qi – sequence: 4 givenname: Xu-Yun surname: Huang fullname: Huang, Xu-Yun – sequence: 5 givenname: Fei surname: Lin fullname: Lin, Fei – sequence: 6 givenname: Zhi-Bin surname: Ke fullname: Ke, Zhi-Bin – sequence: 7 givenname: Qi surname: You fullname: You, Qi – sequence: 8 givenname: Qing-Shui surname: Zheng fullname: Zheng, Qing-Shui – sequence: 9 givenname: Yong surname: Wei fullname: Wei, Yong – sequence: 10 givenname: Xue-Yi surname: Xue fullname: Xue, Xue-Yi – sequence: 11 givenname: Ning orcidid: 0000-0001-7909-7025 surname: Xu fullname: Xu, Ning |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38049827$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kk1vEzEQhleoiLaBP8ABWeLCZYvt_bB9QmmgEFHBBc7W2OvdOtrYwd5Q-u-ZNKU0FUI--OuZdzzj97Q4CjG4onjJ6Bljsn2bGVetKCmvSlqLlpbXT4oTVgtVNlK0Rw_Wx8VpzitKed3U6llxXElaK8nFSRG-vG8rSmwMU4pjJvMFDgKhI6Pf-I4kt0lxSLBe-zAQHwhu8wSTIxaCdYmYG2SG7QjTDpiuHHG_Nsnl7GMgsSfWJ_t5ecHkuaa0el487WHM7sXdPCu-X3z4tvhUXn79uFzML0vbtPVUVlRxZoyVjWmUEIoyoZyiFQhwpq6khF6IXhoLsgdqnIAGqspw0ddG2kZUs2K51-0irPQm-TWkGx3B69uDmAYNafJ2dLpTChrLO0e7BvulZNUpZhpgFHODaVHr3V5rszVr11mHrYLxQPTwJvgrPcSfmtFW1Qq_Z1a8uVNI8cfW5UmvfbZuHCG4uM2aS8zKuBQS0deP0FXcpoC90hylWCXxkX-pAbACH_qIie1OVM-FQIJTqpA6-weFo3Nrjz_ueo_nBwGvHlZ6X-IfuyDA94BFF-Tk-nuEUb3zpN57UmPR-taT-hqD5KMg69FBfmc58OP_Qn8Di4PjuA |
CitedBy_id | crossref_primary_10_1016_j_intimp_2024_113908 |
Cites_doi | 10.1038/s41585-020-00400-w 10.1056/NEJMra1701695 10.1186/s12935-020-01421-6 10.3322/caac.21442 10.1016/j.cmet.2017.09.018 10.1111/and.14406 10.1093/nar/27.1.29 10.1177/0300060521992215 10.3389/fonc.2020.553045 10.1073/pnas.1520686113 10.1016/j.canlet.2016.09.020 10.1080/15476286.2019.1600395 10.1186/s12943-020-01268-5 10.1056/NEJMoa2209454 10.1038/s41391-022-00521-w 10.1016/j.jprot.2017.11.017 10.1038/s41419-021-03877-4 10.1126/science.1238522 10.1038/s41374-022-00743-5 10.1158/0008-5472.CAN-19-3806 10.1083/jcb.201705209 10.3322/caac.21660 10.1007/978-1-4939-6380-5_7 10.1016/j.cell.2018.12.021 10.1016/S0140-6736(14)61947-4 10.1186/s12943-018-0827-8 10.1186/s12943-019-1072-5 10.1038/s41419-021-03582-2 10.1261/rna.043687.113 10.1093/nar/gkw027 10.1016/j.tice.2019.09.001 10.1038/s41388-021-01867-6 10.21873/anticanres.13036 10.1016/j.canlet.2019.12.014 10.1080/15476286.2015.1128065 10.2147/OTT.S157440 10.1186/s13046-021-02029-y 10.1093/nar/gkt1248 10.20892/j.issn.2095-3941.2019.0452 |
ContentType | Journal Article |
Copyright | 2023. The Author(s). COPYRIGHT 2023 BioMed Central Ltd. 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2023 |
Copyright_xml | – notice: 2023. The Author(s). – notice: COPYRIGHT 2023 BioMed Central Ltd. – notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2023 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
DOI | 10.1186/s12967-023-04760-w |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1479-5876 |
EndPage | 22 |
ExternalDocumentID | oai_doaj_org_article_d99a5c2de0d5479983d91b5a10b59ab6 PMC10694902 A775472009 38049827 10_1186_s12967_023_04760_w |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | China |
GeographicLocations_xml | – name: China |
GrantInformation_xml | – fundername: Startup Fund for scientific research, Fujian Medical University grantid: 2020QH2034 – fundername: "Eyas Plan" Youth Top-notch Talent Project of Fujian Province grantid: SCYJHBJRC-XN2021 – fundername: ; grantid: 2020QH2034 – fundername: ; grantid: SCYJHBJRC-XN2021 |
GroupedDBID | --- 0R~ 29L 2WC 53G 5VS 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M CGR CUY CVF ECM EIF NPM PMFND 3V. 7T5 7XB 8FK AZQEC DWQXO H94 K9. PJZUB PKEHL PPXIY PQEST PQUKI 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c564t-30921bbc85b597790179e903a7aeb4388af77f8bca8fa0be7a5a33b27f4b8c573 |
IEDL.DBID | M48 |
ISSN | 1479-5876 |
IngestDate | Wed Aug 27 01:25:06 EDT 2025 Thu Aug 21 18:36:01 EDT 2025 Fri Jul 11 00:15:43 EDT 2025 Sat Jul 26 00:09:53 EDT 2025 Tue Jun 17 22:25:07 EDT 2025 Tue Jun 10 21:14:07 EDT 2025 Thu Apr 03 06:57:47 EDT 2025 Thu Apr 24 22:52:52 EDT 2025 Tue Jul 01 02:59:42 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | CircRNAs Prostate cancer ACACA ND630 |
Language | English |
License | 2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c564t-30921bbc85b597790179e903a7aeb4388af77f8bca8fa0be7a5a33b27f4b8c573 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0001-7909-7025 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12967-023-04760-w |
PMID | 38049827 |
PQID | 2902138547 |
PQPubID | 43076 |
PageCount | 22 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_d99a5c2de0d5479983d91b5a10b59ab6 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10694902 proquest_miscellaneous_2898312878 proquest_journals_2902138547 gale_infotracmisc_A775472009 gale_infotracacademiconefile_A775472009 pubmed_primary_38049827 crossref_primary_10_1186_s12967_023_04760_w crossref_citationtrail_10_1186_s12967_023_04760_w |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-12-04 |
PublicationDateYYYYMMDD | 2023-12-04 |
PublicationDate_xml | – month: 12 year: 2023 text: 2023-12-04 day: 04 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Journal of translational medicine |
PublicationTitleAlternate | J Transl Med |
PublicationYear | 2023 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | AM Grimaldi (4760_CR1) 2022; 26 D Xue (4760_CR36) 2019; 18 C Wang (4760_CR12) 2021; 81 S Raimondo (4760_CR13) 2018; 173 M Liu (4760_CR24) 2019; 16 Z Jiang (4760_CR17) 2021; 40 O Sartor (4760_CR5) 2018; 378 Y Zhong (4760_CR34) 2018; 17 T McHugh (4760_CR15) 2018; 217 H Sung (4760_CR2) 2021; 71 H Xu (4760_CR11) 2020; 472 RL Siegel (4760_CR4) 2018; 68 C Ma (4760_CR35) 2020; 19 B Ye (4760_CR37) 2019; 19 S Jamalzadeh (4760_CR27) 2022; 102 X Ding (4760_CR29) 2022; 54 H Ogata (4760_CR26) 1999; 27 Z Ji (4760_CR33) 2019; 61 T Gao (4760_CR32) 2020; 17 P Glažar (4760_CR22) 2014; 20 H He (4760_CR10) 2021; 49 YP Wu (4760_CR16) 2021; 12 K Nishi (4760_CR40) 2018; 38 WW Du (4760_CR20) 2016; 44 H Guo (4760_CR38) 2020; 10 J Godtman (4760_CR28) 2022; 387 M Rios Garcia (4760_CR39) 2017; 26 JE Wilusz (4760_CR7) 2013; 340 JH Li (4760_CR23) 2014; 42 G Harriman (4760_CR14) 2016; 113 MC Haffner (4760_CR3) 2021; 18 G Attard (4760_CR6) 2016; 387 M Gagliardi (4760_CR19) 2016; 1480 J Luo (4760_CR21) 2017; 384 DB Dudekula (4760_CR25) 2016; 13 JN Vo (4760_CR9) 2019; 176 Y Gao (4760_CR30) 2020; 20 Y Wu (4760_CR31) 2018; 11 X Wang (4760_CR8) 2021; 40 C Liu (4760_CR18) 2021; 12 |
References_xml | – volume: 18 start-page: 79 year: 2021 ident: 4760_CR3 publication-title: Nat Rev Urol doi: 10.1038/s41585-020-00400-w – volume: 378 start-page: 645 year: 2018 ident: 4760_CR5 publication-title: N Engl J Med doi: 10.1056/NEJMra1701695 – volume: 20 start-page: 334 year: 2020 ident: 4760_CR30 publication-title: Cancer Cell Int doi: 10.1186/s12935-020-01421-6 – volume: 19 start-page: 3431 year: 2019 ident: 4760_CR37 publication-title: Mol Med Rep – volume: 68 start-page: 7 year: 2018 ident: 4760_CR4 publication-title: CA Cancer J Clin doi: 10.3322/caac.21442 – volume: 26 start-page: 842 year: 2017 ident: 4760_CR39 publication-title: Cell Metab doi: 10.1016/j.cmet.2017.09.018 – volume: 54 year: 2022 ident: 4760_CR29 publication-title: Andrologia doi: 10.1111/and.14406 – volume: 27 start-page: 29 year: 1999 ident: 4760_CR26 publication-title: Nucleic Acids Res doi: 10.1093/nar/27.1.29 – volume: 49 start-page: 300060521992215 year: 2021 ident: 4760_CR10 publication-title: J Int Med Res doi: 10.1177/0300060521992215 – volume: 10 year: 2020 ident: 4760_CR38 publication-title: Front Oncol doi: 10.3389/fonc.2020.553045 – volume: 113 start-page: E1796 year: 2016 ident: 4760_CR14 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1520686113 – volume: 384 start-page: 39 year: 2017 ident: 4760_CR21 publication-title: Cancer Lett doi: 10.1016/j.canlet.2016.09.020 – volume: 16 start-page: 899 year: 2019 ident: 4760_CR24 publication-title: RNA Biol doi: 10.1080/15476286.2019.1600395 – volume: 19 start-page: 157 year: 2020 ident: 4760_CR35 publication-title: Mol Cancer doi: 10.1186/s12943-020-01268-5 – volume: 387 start-page: 2126 issue: 23 year: 2022 ident: 4760_CR28 publication-title: N Engl J Med doi: 10.1056/NEJMoa2209454 – volume: 26 start-page: 228 year: 2022 ident: 4760_CR1 publication-title: Prostate Cancer Prostatic Dis doi: 10.1038/s41391-022-00521-w – volume: 173 start-page: 1 year: 2018 ident: 4760_CR13 publication-title: J Proteomics doi: 10.1016/j.jprot.2017.11.017 – volume: 12 start-page: 631 year: 2021 ident: 4760_CR18 publication-title: Cell Death Dis doi: 10.1038/s41419-021-03877-4 – volume: 340 start-page: 440 year: 2013 ident: 4760_CR7 publication-title: Science doi: 10.1126/science.1238522 – volume: 102 start-page: 761 year: 2022 ident: 4760_CR27 publication-title: Lab Invest doi: 10.1038/s41374-022-00743-5 – volume: 81 start-page: 3509 year: 2021 ident: 4760_CR12 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-19-3806 – volume: 217 start-page: 2403 year: 2018 ident: 4760_CR15 publication-title: J Cell Biol doi: 10.1083/jcb.201705209 – volume: 71 start-page: 209 year: 2021 ident: 4760_CR2 publication-title: CA Cancer J Clin doi: 10.3322/caac.21660 – volume: 1480 start-page: 73 year: 2016 ident: 4760_CR19 publication-title: Methods Mol Biol doi: 10.1007/978-1-4939-6380-5_7 – volume: 176 start-page: 869 year: 2019 ident: 4760_CR9 publication-title: Cell doi: 10.1016/j.cell.2018.12.021 – volume: 387 start-page: 70 year: 2016 ident: 4760_CR6 publication-title: Lancet doi: 10.1016/S0140-6736(14)61947-4 – volume: 17 start-page: 79 year: 2018 ident: 4760_CR34 publication-title: Mol Cancer doi: 10.1186/s12943-018-0827-8 – volume: 18 start-page: 151 year: 2019 ident: 4760_CR36 publication-title: Mol Cancer doi: 10.1186/s12943-019-1072-5 – volume: 12 start-page: 302 year: 2021 ident: 4760_CR16 publication-title: Cell Death Dis doi: 10.1038/s41419-021-03582-2 – volume: 20 start-page: 1666 year: 2014 ident: 4760_CR22 publication-title: RNA doi: 10.1261/rna.043687.113 – volume: 44 start-page: 2846 year: 2016 ident: 4760_CR20 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkw027 – volume: 61 start-page: 44 year: 2019 ident: 4760_CR33 publication-title: Tissue Cell doi: 10.1016/j.tice.2019.09.001 – volume: 40 start-page: 4338 year: 2021 ident: 4760_CR8 publication-title: Oncogene doi: 10.1038/s41388-021-01867-6 – volume: 38 start-page: 6683 year: 2018 ident: 4760_CR40 publication-title: Anticancer Res doi: 10.21873/anticanres.13036 – volume: 472 start-page: 151 year: 2020 ident: 4760_CR11 publication-title: Cancer Lett doi: 10.1016/j.canlet.2019.12.014 – volume: 13 start-page: 34 year: 2016 ident: 4760_CR25 publication-title: RNA Biol doi: 10.1080/15476286.2015.1128065 – volume: 11 start-page: 1707 year: 2018 ident: 4760_CR31 publication-title: Onco Targets Ther doi: 10.2147/OTT.S157440 – volume: 40 start-page: 227 year: 2021 ident: 4760_CR17 publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-021-02029-y – volume: 42 start-page: D92 year: 2014 ident: 4760_CR23 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkt1248 – volume: 17 start-page: 371 year: 2020 ident: 4760_CR32 publication-title: Cancer Biol Med doi: 10.20892/j.issn.2095-3941.2019.0452 |
SSID | ssj0024549 |
Score | 2.393137 |
Snippet | ND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism. However, the function of... Background ND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism. However, the... BackgroundND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism. However, the... Abstract Background ND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism.... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 877 |
SubjectTerms | ACACA Acetyl-CoA Carboxylase - genetics Acetyl-CoA Carboxylase - metabolism Antibodies Antigens Biomarkers Cell division Cell Line, Tumor Cell Movement - genetics Cell proliferation Cell Proliferation - genetics Cholecystokinin CircRNAs Circular RNA Cytoplasm Disease Enzymes Fatty acids Fluorescence in situ hybridization Gene Expression Regulation, Neoplastic Humans Immunoprecipitation In Situ Hybridization, Fluorescence Kinesins - genetics Kinesins - metabolism Lipid metabolism Lipids Localization Male Medical prognosis Metabolism MicroRNAs - genetics MicroRNAs - metabolism ND630 Oncogenes Prostate cancer Prostatic Neoplasms - genetics Proteins Ribonucleic acid RNA RNA, Circular - genetics Tumor cell lines Up-regulation Wound healing |
SummonAdditionalLinks | – databaseName: DOAJ Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA9yD-KL-G31lAiCD1KubZImfdw7XU7Fe_Lg3sLko1g4u8vuHqf_vTNtumwR9MXXZkKT-cjMtJPfMPa2DMGBCJBDKWMu6UMTaO_yEvA4NCJQ-22qtriozy_l5yt1ddDqi2rCRnjgkXEnoWlA-SrEIiipMTkQoSmdgrJwqgE3gG2jz5uSqQllD9Oe6YqMqU-26NXwQED_lBdS10V-O3NDA1r_n2fygVOaF0weeKDlA3Y_hY58MS75IbsT-0fs7tf0c_wx6y8-1KLgqfh8y5HLZwsOfeDX3boLnPArh2KsH-iueNfzNd34wFiTexL9hrtfSDO0picCjAx5_JnqZHu-arnvNv7Lp2VpTgnr8wm7XH78dnaep3YKuVe13OWiaKrSOW-UI9C5hmwxNoUADdFJYQy0WrfGeTAtFC5qUCCEq3QrnfFKi6fsqF_18TnjrQFkqwoRsyXZthEEuNBiruu1MC6ojJUTd61PWOPU8uLaDjmHqe0oEYsSsYNE7G3G3u_nrEekjb9Sn5LQ9pSEkj08QN2xSXfsv3QnY-9I5JZsGZfnIV1JwE0SKpZdEDygpv9HGTueUaIN-vnwpDQ2nQFbWzUYPwmDJBl7sx-mmVTX1sfVDdIYXBSGCNpk7NmoY_stCYPZm6lwtplp32zP85G--z4ghJd0nRlf_-J_cOklu1eR5VANjzxmR7vNTXyFkdjOvR6M7jfXai71 priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgL4k2gICMhcUBRk9iOnRPaFlYFRE9U2ps1fgQileyyu1Xbf89M1rtthNRrPFZsz8tjj79h7H0ZggMRIIdSxlzSQRNo7_IS0BwaEaj8NmVbnNTHp_LbTM3SgdsqpVVubeJgqMPc0xn5QdWgNxJGSf1p8TenqlF0u5pKaNxl9wi6jFK69Ow64JIY_Gwfypj6YIW-Dc0Ceqm8kLou8ouRMxow-_-3zDdc0zht8oYfmj5iD9MGkk82HH_M7sT-Cbv_I12RP2X9yedaFDyloK84rvXRhEMf-Fm36AInFMshJesPOi3e9XxB7z5wx8k9CcCSuyukGQrUEwHuD3m8TNmyPZ-33HdL__3rtDSHhPj5jJ1Ov_w8Os5TUYXcq1quc1E0VemcN8oR9FxDGhmbQoCG6KQwBlqtW-M8mBYKFzUoEMJVupXOeKXFc7bXz_v4kvHWAC6rChFjJtm2EQS40GLE67UwLqiMldvVtT4hjlPhizM7RB6mthuOWOSIHThiLzL2cddnscHbuJX6kJi2oySs7OHDfPnLJtWzoWlA-SrEIqD0YHgpQlM6BWWBKwCuztgHYrkljcbheUgPE3CShI1lJwQSqOkWKWP7I0rURD9u3gqNTZZgZa_lNmPvds3Uk7Lb-jg_RxqDg8KNgjYZe7GRsd2UhMEYzlTY24ykbzTncUvf_R5wwkt61Iy_f3X7uF6zBxXpBOXoyH22t16exze401q7t4M6_QPt5CZM priority: 102 providerName: ProQuest |
Title | ND630 controls ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003 |
URI | https://www.ncbi.nlm.nih.gov/pubmed/38049827 https://www.proquest.com/docview/2902138547 https://www.proquest.com/docview/2898312878 https://pubmed.ncbi.nlm.nih.gov/PMC10694902 https://doaj.org/article/d99a5c2de0d5479983d91b5a10b59ab6 |
Volume | 21 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELf2ISFeEN8ERmUkJB5QIInt2HlAqB2rBmgVmqg08WL5K1CppKXttO2_585NyyImJF76EJ_T-D58d8n5d4S8zL23hnmTmpyHlOOLJiOdTXMD26FiHttvY7XFqDwe809n4myHbNodtQxc3pjaYT-p8WL65vLX1Xsw-HfR4FX5dgk-C8wdvE-acVlm6cUu2QfPJNFQT7j6g70nYjicc1mlAraBzSGaG-_RcVQRz__vXfua2-qWVF7zUcO75E4bXNL-WhvukZ3Q3Ce3TtrP5w9IM_pQsoy25elLCnI47FPTeDqdzCeeIsJlLNf6CQ6NTho6xzMhEI1Sh8qxoPYKaGLzeiSA2JGGy7aStqGzmrrJwn3-OMzVANFAH5Lx8Ojr4XHaNlxInSj5KmVZVeTWOiUswtJVaK2hypiRJljOlDK1lLWyzqjaZDZIIwxjtpA1t8oJyR6RvWbWhCeE1soAW4UPkE_xug6GGetryIadZMp6kZB8w13tWjRybIox1TErUaVeS0SDRHSUiL5IyOvtnPkai-Of1AMU2pYScbTjhdniu27NUvuqMsIVPmRegFZUoJ1VboXJM-CAsWVCXqHINeofPJ4z7aEFWCTiZuk-AghK_MKUkIMOJVip6w5vlEZvlFwXFURYTAFJQl5sh3EmVr41YXYONAoeCoIIqRLyeK1j2yUxBfmdKmC26mhfZ83dkWbyI2KI53jgGf7-6X_x9Bm5XaCJYDkPPyB7q8V5eA5B2cr2yK48kz2yPzgafTntxVcbvWh98Hs6-PYbZNM0Qg |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3bbtMw1BqdBLwg7gQGGAnEA4qWxE7sPCDUbqtaulUIbdLejG8ZlUZa2k5lP8U3ck6adIuQ9rbX-Dixfe7xuRDyPnbOaOZ0qGPuQ44_mrSwJow1iEPJHLbfxmiLcTY44V9P09Mt8rfJhcGwykYmVoLaTS3-I99NctBGTKZcfJn9DrFrFN6uNi001mQx8pcrcNkWn4f7gN8PSdI_ON4bhHVXgdCmGV-GLMqT2BgrU4O113IkSZ9HTAvtDWdS6kKIQhqrZaEj44VONWMmEQU30qaCwXvvkG3OwJXpkO3ewfjb96vqfuBuNak5MttdgDYFQQR6MYy4yKJw1VJ_VZeA_3XBNWXYDtS8pvn6D8mD2mSl3TWNPSJbvnxM7h7Vl_JPSDnez1hE66D3BQXs7nWpLh09n8wmjmLdzCoI7BeoSTop6QwzTcDGpRZJbk7NJcCcVX3EAAAsUur_1PG5JZ0W1E7mdjTsx7KHNUafkpNbOfBnpFNOS_-C0EJqONbUefDSeFF4zbRxBfjYVjBpXBqQuDldZesa59hq41xVvo7M1BojCjCiKoyoVUA-bebM1hU-boTuIdI2kFidu3ownZ-pmtmVy3Od2sT5yAG9gkPLXB6bVMcRnIA2WUA-IsoVyhBYntV1KgRsEqtxqS6WJRR4bxWQnRYk8L5tDzdEo2rZs1BXnBKQd5thnInxdKWfXgCMhEWBaSJkQJ6vaWyzJSbBa5QJzJYt6mvtuT1STn5WlcljTKOGz7-8eV1vyb3B8dGhOhyOR6_I_QT5AyOE-A7pLOcX_jXYeUvzpmYuSn7cNj__A77VZNU |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=ND630+controls+ACACA+and+lipid+reprogramming+in+prostate+cancer+by+regulating+the+expression+of+circKIF18B_003&rft.jtitle=Journal+of+translational+medicine&rft.au=Wu%2C+Yu-Peng&rft.au=Zheng%2C+Wen-Cai&rft.au=Huang%2C+Qi&rft.au=Huang%2C+Xu-Yun&rft.date=2023-12-04&rft.issn=1479-5876&rft.eissn=1479-5876&rft.volume=21&rft.issue=1&rft_id=info:doi/10.1186%2Fs12967-023-04760-w&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12967_023_04760_w |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon |